mk-944a
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002424)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Multidrug resistance protein 3INHIBITOR
ABCB4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- l 756423
- l 756,423
- l-756423
- l-756423
- l-756423
- l-756,423
- mk 944a
- mk-944a
- n-(2(r)-hydroxy-1(s)-indanyl)-2(r)-phenylmethyl-4(s)-hydroxy-5-(1-(4-(2-benzo(b)furanylmethyl)-2(s)-n'-(tert-butylcarboxamido)piperazinyl))pentanamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002452 | Phase 2 | Jan 17, 2000 | Merck |
| NCT00002424 | Phase 2 | Nov 2, 1999 | Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 1 | 1999 |
1 organizations
Page 1 / 1